title: Severe skin necrosis after rituximab-CHOP therapy.
authors.forename: I P G
authors.initials: IP
authors.lastname: Botden
authors.forename: M B
authors.initials: MB
authors.lastname: Leys
authors.forename: A A
authors.initials: AA
authors.lastname: van Houten
authors.forename: R P
authors.initials: RP
authors.lastname: Peeters
mesh_terms: D000368:Aged; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects; D058846:Antibodies, Monoclonal, Murine-Derived; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects*; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000009:adverse effects; D004317:Doxorubicin / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D006801:Humans; D009336:Necrosis; D011239:Prednisolone / Q000008:administration & dosage / Q000009:adverse effects; D000069283:Rituximab; D012871:Skin Diseases / Q000139:chemically induced* / Q000473:pathology*; D014750:Vincristine / Q000008:administration & dosage / Q000009:adverse effects
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000069283:Rituximab; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011239:Prednisolone